What's Replacing Fentanyl in the Drug Supply?

Clinically Reviewed By: Brian Wind, PhD

If you’re asking what’s replacing fentanyl in the drug supply, here’s the honest answer. Fentanyl deaths have fallen for a third straight year, and that progress is real. At the same time, the supply has grown more complicated. Veterinary sedatives like xylazine and now medetomidine, a shifting cast of ultra-potent synthetic opioids called nitazenes, and newer industrial additives are turning up alongside or in place of fentanyl. Naloxone still saves lives and you should always use it, though it doesn’t reverse the sedatives, and standard medication treatment doesn’t ease their withdrawal. That’s why getting off today’s supply safely often takes a program built for more than a single drug.

Key Takeaways

Overdose deaths dropped almost 14% in 2025, a third straight annual decline driven mostly by fewer fentanyl deaths.
The danger now comes more from unpredictability than from any single drug. You can’t know what’s actually in a bag or a pill.
Xylazine and the faster-growing sedative medetomidine are not opioids, so naloxone doesn’t reverse their effects.
Medetomidine withdrawal can be life-threatening, and the medications that work for opioid withdrawal don’t fully address it.
Polysubstance dependence is now the norm, which is why comprehensive, medically supervised treatment matters more than ever.

The Good News First: Overdose Deaths Are Falling

Provisional figures from the CDC’s National Center for Health Statistics estimate about 69,973 drug overdose deaths in the United States during 2025, down almost 14% from the 81,313 deaths estimated in 2024. That marks a third consecutive annual decline, bringing deaths to their lowest level since before the pandemic. Deaths involving opioids fell from roughly 55,296 to 44,564 over the same period.

Enforcement data points the same direction. The Drug Enforcement Administration reported that 29% of the fentanyl pills its labs analyzed in fiscal year 2025 contained a potentially lethal dose, a sharp drop from 76% two years earlier, with average powder purity falling as well. Wider naloxone access, expanded treatment, and pressure on the supply chain all appear to be helping. Those are lives saved, and that deserves to be said plainly.

Why “the Fentanyl Crisis Is Over” Misses the Point

The drop in deaths is real progress, and it tells only part of the story. Overdose counts measure how many people died. They say little about how knowable the supply has become, and on that measure things have moved the wrong way.

As fentanyl has gotten weaker and harder to source, suppliers have folded in other substances to stretch product, prolong effects, or replace what’s missing. A single bag or counterfeit pill can now contain a fentanyl analog, a veterinary sedative, a novel synthetic opioid, and an industrial chemical all at once. The new danger is unpredictability. Two purchases from the same source on the same day can carry different ingredients, and the person using has no way to know. For anyone trying to use more carefully, or for a family member trying to keep someone alive, that uncertainty is the part of the crisis that has gotten harder.

What’s Replacing Fentanyl in the Drug Supply Now

Here’s what labs and the DEA are flagging most often, and why each calls for a different response.

Xylazine (“Tranq”)

Xylazine is a veterinary sedative and an alpha-2 adrenergic agonist, which means it works on a different receptor system than opioids do. According to the National Institute on Drug Abuse, xylazine slows breathing, heart rate, and blood pressure to dangerously low levels, and it can produce the severe skin wounds that gave “tranq” its grim reputation. It spread widely through the fentanyl supply over recent years. Because xylazine is not an opioid, the standard overdose response only partly applies, a point we’ll come back to.

Medetomidine (“Dex”), the Faster-Growing Sedative

Medetomidine is another alpha-2 sedative, and it’s spreading fast enough to displace xylazine in some markets. Drug-checking data from the Center for Forensic Science Research and Education found that across the Mid-Atlantic region, the share of fentanyl samples containing xylazine fell from 97% in early 2024 to about 21% by late 2025, while medetomidine climbed from almost none to roughly 88%. Philadelphia shows the same pattern as an illustrative local snapshot rather than a national one. Estimates put medetomidine at many times the potency of xylazine, which is why such a fast takeover matters for overdose response and withdrawal.

Nitazenes, a Synthetic Opioid Class With Wide-Ranging Potency

Nitazenes are a family of synthetic opioids first developed in the 1950s and never approved for medical use. Research from the NIDA Intramural Research Program shows the class varies widely in strength. Certain analogs are substantially more potent than fentanyl in laboratory studies, while others land closer to it or below, and how that translates to real human exposure remains uncertain. The DEA reports identifying more than 20 distinct nitazene compounds since 2020, with new ones appearing as older ones get scheduled. They often go undetected on routine drug screens, which is part of what makes them hard to track.

Newer Additives (Cychlorphine, BTMPS) and Why Drug Lists Go Stale

The list keeps moving. In a May 2026 public safety advisory, the DEA named cychlorphine, a synthetic opioid first flagged in forensic alerts in early 2026, among the emerging substances complicating overdose response. Labs have also reported BTMPS, an industrial plastic stabilizer, turning up in samples for reasons that aren’t fully understood. The broader point matters more than any single name. By the time a substance reaches the headlines, the supply has often shifted again, so response can’t depend on knowing the ingredients in advance.

Why Narcan Isn’t Enough Anymore (and Why You Should Still Carry It)

Naloxone, sold as Narcan, works by knocking opioids off the receptors they bind to. It reverses fentanyl, heroin, and the nitazenes, since all of those are opioids, though some nitazenes may need more than one dose because they cling to receptors longer. That part of naloxone’s job still works well.

The sedatives are a different story. The CDC and NIDA are both clear that naloxone does not reverse xylazine or medetomidine, because those drugs aren’t opioids. In a mixed overdose, naloxone can restore breathing from the opioid while heavy sedation from the alpha-2 component continues. That can look, frighteningly, like the naloxone “didn’t work,” when in fact it did its job and a second drug is still in play.

So the bottom line hasn’t changed. Always give naloxone for any suspected overdose. It can’t hurt if no opioid is involved, and an opioid almost always is. Then call 911 right away and stay with the person, because the sedation may outlast the naloxone and they need medical care. Carry it, use it, and call for help. That advice matters more now than ever.

Why Treatment Looks Different Now

If the supply has changed this much, it follows that getting off it safely has changed too. The clearest example is alpha-2 withdrawal. The CDC’s Morbidity and Mortality Weekly Report described 165 people hospitalized in Philadelphia over five months with a newly recognized medetomidine withdrawal syndrome marked by severe spikes in blood pressure and heart rate. Most needed intensive care. The syndrome resisted the medications that usually manage fentanyl and xylazine withdrawal, and it responded instead to close medical monitoring and specialized sedation. Withdrawal from these sedatives can be life-threatening on its own.

This is the heart of why a medication-only or tough-it-out approach falls short for today’s supply. Buprenorphine and methadone treat opioid dependence, and they remain valuable tools a clinician may recommend after evaluation. They don’t ease alpha-2 withdrawal, which needs different medications and hands-on monitoring. Since most people in the supply now are exposed to several substances at once, the picture points toward comprehensive, medically supervised care that can screen for what’s present and manage more than one withdrawal at a time. Co-occurring depression, anxiety, and trauma make that even more true.

If you’re weighing your options, or watching someone you love try to, it helps to talk it through with people who manage these situations every day. JourneyPure At The River’s team in Murfreesboro answers questions 24/7 about what today’s supply means for safe withdrawal.

How JourneyPure At The River Approaches Today’s Polysubstance Reality

JourneyPure At The River sits on a 127-acre campus along the Stones River near Nashville, and its model fits the polysubstance reality squarely. Care starts with medically supervised detox, where staff monitor for the autonomic instability that alpha-2 sedatives produce and adjust treatment as symptoms appear, rather than assuming a single, predictable opioid withdrawal. From there, the full continuum runs through residential stays that average about 30 days and into outpatient care, so stabilization leads into recovery work.

Because the conditions underneath addiction rarely travel alone, dual diagnosis treatment for depression, anxiety, and trauma is built into the program rather than bolted on. Where it fits a person’s clinical picture, medication-assisted treatment is one option a clinician may recommend after evaluation. Evidence-based therapy is paired with experiential work like equine therapy, ropes courses, and time on the water, used as clinical tools for people learning to live differently.

Much of the staff has lived this. Our strength is our people, many of them in recovery themselves, which builds the trust that comes from recognition. JourneyPure reports that 84% of its alumni sustain their recovery, an aggregate network figure rather than a promise for any one person. The National Institute on Drug Abuse puts relapse rates for substance use disorders at 40% to 60%, in line with other chronic conditions, which is why ongoing support like alumni programming and JourneyPure Coaching matters as much as the first 30 days.

Recovery is not for the faint-hearted, and you don’t have to figure out today’s supply on your own. You can do it, and we will show you how. To talk with someone now about detox, dual diagnosis, or admissions, call JourneyPure At The River at (629) 222-9449. Help is available 24/7.

Frequently Asked Questions

Is the Fentanyl Crisis Over?

No, though there’s real progress to point to. Overdose deaths fell almost 14% in 2025, the third straight annual decline, according to the CDC. The supply itself has grown more complicated and less predictable, so the risk has shifted rather than disappeared.

What Is Replacing Fentanyl in the Drug Supply?

Fentanyl is increasingly mixed with or replaced by other substances, including the veterinary sedatives xylazine and medetomidine, a class of synthetic opioids called nitazenes, and newer additives such as cychlorphine and the industrial chemical BTMPS. The DEA has warned that these combinations make the supply more unpredictable, and people who use drugs usually have no way to know what’s actually present.

What Is Medetomidine (Dex), and How Is It Different From Xylazine?

Medetomidine is a veterinary sedative in the same alpha-2 agonist family as xylazine, and it’s now displacing xylazine in some regional supplies. Estimates suggest it is many times more potent, with longer sedation and a more severe withdrawal. Like xylazine, it is not an opioid, so naloxone does not reverse its effects.

Does Narcan Work on Xylazine or Medetomidine?

No. Naloxone reverses opioids, and xylazine and medetomidine are sedatives from a different drug class. You should still give naloxone for any suspected overdose, because opioids like fentanyl are almost always present, then call 911, since the sedation can continue after the naloxone wears off.

Are Nitazenes Stronger Than Fentanyl?

Some are, and some aren’t. Laboratory studies show certain nitazene analogs are substantially more potent than fentanyl while others are similar or weaker, and their real-world potency in people is still uncertain. Naloxone does reverse them, though stronger analogs may require more than one dose.

Why Does Polysubstance Use Make Treatment Harder?

Polysubstance use makes treatment harder because each substance can require a different response, and one medication can’t address them all. A person may face opioid withdrawal, alpha-2 sedative withdrawal, and a co-occurring mental health condition at once, which calls for medically supervised care that can screen for what’s present and manage several issues together.

What Kind of Treatment Do I Need to Get Off Today’s Drug Supply?

For today’s supply, the safest path usually starts with medically supervised detox at a program equipped to handle more than a single drug, with staff who can monitor for sedative-driven withdrawal and treat co-occurring conditions. If you’re not sure what you need, a confidential phone evaluation is a good first step. This article is for general information and isn’t a substitute for personalized medical advice.

Crisis and Emergency Resources

If you or someone you know is in a substance use or mental health crisis, help is available now. Contact the SAMHSA National Helpline at 1-800-662-HELP (4357) for free, confidential treatment referrals 24/7. Reach the 988 Suicide and Crisis Lifeline by calling or texting 988. The Crisis Text Line is available by texting HOME to 741741. For emergencies, call 911.

Learn More

Will Long

What’s Replacing Fentanyl in the Drug Supply?